Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
1994-12-02
2003-12-09
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600, C514S012200, C530S350000, C530S351000
Reexamination Certificate
active
06660256
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the isolation, purification and characterization of proteins that influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. This invention further relates to the cloning and expression of a protein ligand capable of binding to and activating mpl, a member of the cytokine receptor superfamily. This application further relates to the use of these proteins alone or in combination with other cytokines to treat thrombocytopenia.
BACKGROUND OF THE INVENTION
I. Megakaryocytopoiesis
It is known that bone marrow pluripotent stem cells differentiate into megakaryocytic, erythrocytic, and myelocytic cell lines. It is believed there is also a line of committed cells between stem cells and megakaryocytes. The earliest recognizable member of the megakaryocyte (meg) family are the megakaryoblasts. These cells are initially 20 to 30 &mgr;m in diameter having basophilic cytoplasm and a slightly irregular nucleus with loose, somewhat reticular chromatin and several nucleoli. Later, megakaryoblasts may contain up to 32 nuclei, but the cytoplasm remains sparse and immature. As maturation proceeds, the nucleus becomes more lobulate and pyknotic, the cytoplasm increases in quantity and becomes more acidophilic and granular. The most mature cells of this family may give the appearance of releasing platelets at their periphery. Normally, less than 10% of megakaryocytes are in the blast stage and more than 50% are mature. Arbitrary morphologic classifications commonly applied to the megakaryocyte series: are megakaryoblast for the earliest form; promegakaryocyte or basophilic megakaryocyte for the intermediate form; and mature (acidophilic, granular, or platelet-producing) megakaryocyte for the late forms. The mature megakaryocyte extends filaments of cytoplasm into sinusoidal spaces where they detach and fragment into individual platelets (Williams et al.,
Hematology,
1972).
Megakaryocytopoiesis is believed to involve several regulatory factors (Williams et al.,
Br. J. Haematol.,
52:173 [1982] and Williams et al.,
J. Cell Physiol.
110:101 [1982]). The early level of megakaryocytopoiesis is postulated as being mitotic, concerned with cell proliferation and colony initiation from CFU-meg but is not affected by platelet count (Burstein et al.,
J. Cell Physiol.
109:333 [1981] and Kimura et al.,
Exp. Hematol.
13:1048 [1985]). The later stage of maturation is non-mitotic, involved with nuclear polyploidization and cytoplasmic maturation and is probably regulated in a feedback mechanism by peripheral platelet number (Odell et al.,
Blood
48:765 [1976] and Ebbe et al.,
Blood
32:787 [1968]). The existence of a distinct and specific megakaryocyte colony-stimulating factor (meg-CSF) has been disputed (Mazur, E.,
Exp. Hematol.
15:340-350 [1987]). Although. meg-CSF's have been partly purified from experimentally produced thrombocytopenia (Hill et al.,
Exp. Hematol.
14:752 [1986]) and human embryonic kidney conditioned medium [CM] (McDonald et al.,
J. Lab. Clin. Med.
85:59 [1975]) and in man from aplastic anemia and idiopathic thrombocytopenic purpura urinary extracts (Kawakita et al.,
Blood
6:556 [1983]) and plasma (Hoffman et al.,
J. Clin. Invest.
75:1174 [1985]), their physiological function is as yet unknown in most cases. The conditioned medium of pokeweed mitogen-activated spleen cells (PWM-SpCM) and the murine myelomonocyte cell line WEHI-3 (WEHI-3CM) have been used as megakaryocyte potentiators. PWM-SpCM contains factors enhancing CFU-meg growth (Metcalf et al.,
Pro. Natl. Acad. Sci., USA
72:1744-1748 [1975]; Quesenberry et al.,
Blood
65:214 [1985]; and Iscove, N. N., in
Hematopoietic Cell Differentiation, ICN
-
UCLA Symposia on Molecular and Cellular Biology,
Vol. 10, Golde et al., eds. [New York, Academy Press] pp 37-52 [1978]), one of which is interleukin-3 (IL-3), a multilineage colony stimulating factor (multi-CSF [Burstein, S. A.,
Blood Cells
11:469 [1986]). The other factors in this medium have not yet been identified and isolated. WEHI-3 is a murine myelomonocytic cell line secreting relatively large amounts of IL-3 and smaller amounts of GM-CSF. IL-3 has been recently purified and cloned (Ihle et al.,
J. Immunol.
129:2431 [1982]) and has been found to potentiate the growth of a wide range of hemopoietic cells (Ihle et al.,
J. Immunol.
13:282 [1983]). IL-3 has also been found to synergize with many of the known hemopoietic hormones or growth factors (Bartelmez et al.,
J. Cell Physiol.
122:362-369 [1985] and Warren et al.,
Cell
46:667-674 [1988]), including both erythropoietin (EPO) and H-1 (later known as interleukin-1 or IL-1), in the induction of very early multipotential precursors and the formation of very large mixed hemopoietic colonies.
Other sources of megakaryocyte potentiators have been found in the conditioned media of murine lung, bone, macrophage cell lines, peritoneal exudate cells and human embryonic kidney cells. Despite certain conflicting data (Mazur, E.,
Exp. Hematol.
15:340-350 [1987]), there is some evidence (Geissler et al.,
Br. J. Haematol.
60:233-238 [1985]) that activated T lymphocytes rather than monocytes play an enhancing role in megakaryocytopoiesis. These findings suggest that activated T-lymphocyte secretions such as interleukins may be regulatory factors in meg development (Geissler et al.,
Exp. Hematol.
15:845-853 [1987]). A number of studies on megakaryocytopoiesis with purified EPO (Vainchenker et al.,
Blood
54:940 [1979]; McLeod et al.,
Nature
261:492-4 [1976]; and Williams et al.,
Exp. Hematol.
12:734 [1984]) indicate that this hormone has an enhancing effect on meg colony formation. More recently this has been demonstrated in both serum-free and serum-containing cultures and in the absence of accessory cells (Williams et al.,
Exp. Hematol.
12:734 [1984]). EPO was postulated to be involved more in the single and two-cell stage aspects of megakaryocytopoiesis as opposed to the effect of PWM-SpCM which was involved in the four-cell stage of megakaryocyte development. The interaction of all these factors on both early and late phases of megakaryocyte development remains to be elucidated.
Other documents of interest include: Eppstein et al., U.S. Pat. No. 4,962,091; Chong, U.S. Pat. No. 4,879,111; Fernandes et al., U.S. Pat. No. 4,604,377; Wissler et al., U.S. Pat. No. 4,512,971; Gottlieb, U.S. Pat. No. 4,468,379; Kogan et al., U.S. Pat. No. 5,250,732; Kimura et al.,
Eur. J. Immunol.,
20(9): 1927-1931 (1990); Secor, W. E. et al.,
J. of Immunol.,
144(4): 1484-1489 (1990); Warren, D. J., et al.,
J. of Immunol.
140(1): 94-99 (1988); Warren, M. K. et al.,
Exp. Hematol.,
17(11): 1095-1099 (1989); Bruno, E., et al.,
Exp. Hematol.,
17(10): 1038-1043 (1989); Tanikawa et al.,
Exp. Hematol.,
17(8): 883-888 (1989); Koike et al.,
Blood,
75(12): 2286-2291 (1990); Lotem, et al.,
Blood,
75(5): 1545-1551 (1989); Rennick, D., et al.,
Blood,
73(7): 1828-1835 (1989); and Clutterbuck, E. J., et al.,
Blood,
73(6): 1504-1512 (1989).
II. Thrombocytopenia
Platelets are critical elements of the blood clotting mechanism. Depletion of the circulating level of platelets, called thrombocytopenia, occurs in various clinical conditions and disorders. Thrombocytopenia is commonly defined as a platelet count below 150×10
9
per liter. The major causes of thrombocytopenia can be broadly divided into three categories on the basis of platelet life span, namely; (1) impaired production of platelets by the bone marrow, (2) platelet sequestration in the spleen (splenomegaly), or (3) increased destruction of platelets in the peripheral circulation (e.g. autoimmune thrombocytopenia or chemo- and radiation therapy). Additionally, in patients re
de Sauvage Frederic J.
Eaton Dan L.
Genetech, Inc.
Schwartz Timothy R.
Spector Lorraine
LandOfFree
Porcine mpl ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Porcine mpl ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porcine mpl ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3101816